Skip to main content
Premium Trial:

Request an Annual Quote

Natera Launches Follow-On Stock Offering at $35 Per Share

The story has been corrected to reflect the gross proceeds from the offering are expected to be about $400 million, not $350 million as previously stated.

NEW YORK – Natera announced the launch of a follow-on public offering of 11,430,000 shares of common stock at a public price of $35 per share.

The offering is for approximately $400 million of its shares, Natera said adding it is also granting its underwriters a 30-day option to purchase up to an additional 1,714,500 shares of common stock at the public offering price for an additional $52.5 million in proceeds. The offering is expected to close on Nov. 18, pursuant to customary closing conditions.

Morgan Stanley, Cowen, and SVB Securities are acting as joint book-running managers for the offering. Baird is acting as lead manager, with BTIG, Canaccord Genuity, Craig-Hallum, and Stephens acting as co-managers.

As of Sept. 30, Austin, Texas-based Natera had $57.0 million in cash and cash equivalents, $464.1 million in short-term investments, and $86,000 in restricted cash. Earlier this month, Natera raised its annual financial guidance on the back of strong test volume growth and near-term reimbursement opportunities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.